#Latest news with #PeterMeursAU Financial Review01-05-2025BusinessAU Financial ReviewBiotech Dimerix lands $940m licensing deal for kidney drug salesASX-listed Dimerix has landed one of the biggest licensing deals by an Australian biotechnology company after US pharmaceutical group Amicus Therapeutics agreed to $940 million in payments for future sales of its kidney disease drug. Shares in Melbourne-based Dimerix were trading 50 per cent higher on news of the breakthrough on Thursday afternoon, valuing the company at $400 million. The biotech group counts former Fortescue Metals and WorleyParsons executive Peter Meurs as its biggest shareholder, with a 13.5 per cent stake.
AU Financial Review01-05-2025BusinessAU Financial ReviewBiotech Dimerix lands $940m licensing deal for kidney drug salesASX-listed Dimerix has landed one of the biggest licensing deals by an Australian biotechnology company after US pharmaceutical group Amicus Therapeutics agreed to $940 million in payments for future sales of its kidney disease drug. Shares in Melbourne-based Dimerix were trading 50 per cent higher on news of the breakthrough on Thursday afternoon, valuing the company at $400 million. The biotech group counts former Fortescue Metals and WorleyParsons executive Peter Meurs as its biggest shareholder, with a 13.5 per cent stake.
01-05-2025
